[{"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-001", "question": "A 68-year-old man with a history of severe COPD (FEV1 35% predicted) and chronic hypercapnia (baseline PaCO2 55 mmHg) presents with acute-on-chronic hypercapnic respiratory failure requiring non-invasive ventilation. After 48 hours of improvement, his arterial blood gas shows pH 7.36, PaCO2 48 mmHg, PaO2 85 mmHg on 2 L/min nasal cannula. He is alert and comfortable. The next most appropriate step in management is:", "options": ["Gradually wean and discontinue supplemental oxygen to target a PaO2 of 55-60 mmHg", "Continue current oxygen therapy and plan for discharge home with home oxygen", "Increase oxygen flow to achieve a PaO2 > 88 mmHg", "Obtain a venous blood gas to confirm the arterial values", "Initiate acetazolamide 250 mg twice daily to accelerate renal compensation"], "answer": "A", "answer_index": 0, "explanation": "In patients with chronic hypercapnia, the hypoxic drive is a primary respiratory stimulus. Over-oxygenation can suppress this drive, leading to worsening hypercapnia and acidosis. The target PaO2 is 55-60 mmHg or SpO2 88-92%, which provides adequate oxygenation while minimizing the risk of CO2 retention. Increasing oxygen (C) is dangerous, and acetazolamide (E) is not indicated in acute-on-chronic respiratory failure as it can worsen acidosis by inhibiting compensatory metabolic alkalosis.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: Severe COPD (FEV1 35% predicted), chronic hypercapnia (baseline PaCO2 55 mmHg), acute-on-chronic hypercapnic respiratory failure improved after 48 hours on NIV, current ABG pH 7.36, PaCO2 48 mmHg, PaO2 85 mmHg on 2 L/min nasal cannula, patient alert and comfortable. These suggest need to manage oxygen to avoid suppressing hypoxic drive, but absence of baseline room air PaO2 or SpO2 prevents determining if discontinuation of oxygen achieves target without causing hypoxia.\\nMain logical issue(s), if any: Underspecified (U); the stem misses critical detail on room air oxygenation status, requiring unstated assumption that patient's room air PaO2 falls within 55-60 mmHg to defend A as best. This makes it impossible to uniquely select A without inventing facts, as severe COPD often implies baseline hypoxemia necessitating titrated oxygen rather than full discontinuation.\\nMain medical accuracy issue(s), if any: Mostly consistent with guidelines (e.g., BTS/ATS) for targeting SpO2 88-92% or PaO2 ~55-60 mmHg in hypercapnic COPD to prevent CO2 retention. However, rationale for E inaccurately states acetazolamide worsens acidosis by inhibiting compensatory metabolic alkalosis; it actually induces mild metabolic acidosis to stimulate ventilation and is sometimes used adjunctively in weaning, though not the next step here. Option A's phrasing is clinically unrealistic without baseline data.\\nMinimal fix: Add to stem: 'Room air PaO2 is 58 mmHg prior to discharge assessment.'\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: Severe COPD (FEV1 35% predicted), chronic hypercapnia (baseline PaCO2 55 mmHg), acute-on-chronic hypercapnic respiratory failure improved after 48 hours on NIV, current ABG pH 7.36, PaCO2 48 mmHg, PaO2 85 mmHg on 2 L/min nasal cannula, patient alert and comfortable. These suggest need to manage oxygen to avoid suppressing hypoxic drive, but absence of baseline room air PaO2 or SpO2 prevents determining if discontinuation of oxygen achieves target without causing hypoxia.\nMain logical issue(s), if any: Underspecified (U); the stem misses critical detail on room air oxygenation status, requiring unstated assumption that patient's room air PaO2 falls within 55-60 mmHg to defend A as best. This makes it impossible to uniquely select A without inventing facts, as severe COPD often implies baseline hypoxemia necessitating titrated oxygen rather than full discontinuation.\nMain medical accuracy issue(s), if any: Mostly consistent with guidelines (e.g., BTS/ATS) for targeting SpO2 88-92% or PaO2 ~55-60 mmHg in hypercapnic COPD to prevent CO2 retention. However, rationale for E inaccurately states acetazolamide worsens acidosis by inhibiting compensatory metabolic alkalosis; it actually induces mild metabolic acidosis to stimulate ventilation and is sometimes used adjunctively in weaning, though not the next step here. Option A's phrasing is clinically unrealistic without baseline data.\nMinimal fix: Add to stem: 'Room air PaO2 is 58 mmHg prior to discharge assessment.'", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-002", "question": "A 45-year-old woman with a history of recurrent calcium oxalate kidney stones presents with acute pancreatitis. Lipase is 1200 U/L, calcium 11.8 mg/dL, PTH 85 pg/mL (normal 10-65). She is not on lithium or thiazides. A pancreatic protocol CT shows diffuse gland enlargement but no necrosis or ductal dilation. The most likely underlying etiology of her pancreatitis is:", "options": ["Primary hyperparathyroidism due to parathyroid adenoma", "Autoimmune pancreatitis (IgG4-related disease)", "Hereditary pancreatitis due to PRSS1 mutation", "Hypertriglyceridemia-induced pancreatitis", "Pancreatitis secondary to a gastrinoma (Zollinger-Ellison syndrome)"], "answer": "A", "answer_index": 0, "explanation": "The triad of hypercalcemia, elevated PTH, and recurrent calcium oxalate stones is classic for primary hyperparathyroidism. Hypercalcemia is a known, though uncommon, cause of pancreatitis. The elevated PTH confirms primary hyperparathyroidism, not secondary causes. While hypertriglyceridemia (D) can cause pancreatitis, it doesn't explain the hypercalcemia and elevated PTH. Gastrinoma (E) is associated with ulcers and diarrhea, not typically hypercalcemia and stones.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Recurrent calcium oxalate kidney stones, hypercalcemia (11.8 mg/dL), elevated PTH (85 pg/mL) confirming primary hyperparathyroidism, acute pancreatitis with elevated lipase (1200 U/L), absence of lithium/thiazide use, and CT showing diffuse pancreatic enlargement without necrosis or ductal dilation. These clues point to hypercalcemia from primary hyperparathyroidism as the etiology of pancreatitis, with stones as a classic manifestation. Main logical issue(s): None; the stem provides sufficient discriminating details to identify A as the unique best answer, with alternatives less fitting due to lack of supporting features (e.g., no IgG4 evidence for B, no family history or early onset for C, no triglyceride levels for D, no ulcer/diarrhea for E). Main medical accuracy issue(s): None; aligns with established knowledge that primary hyperparathyroidism causes hypercalcemia-induced pancreatitis (though uncommon) and nephrolithiasis, per guidelines like those from the American Association of Clinical Endocrinologists. The rationale correctly distinguishes from secondary causes. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Recurrent calcium oxalate kidney stones, hypercalcemia (11.8 mg/dL), elevated PTH (85 pg/mL) confirming primary hyperparathyroidism, acute pancreatitis with elevated lipase (1200 U/L), absence of lithium/thiazide use, and CT showing diffuse pancreatic enlargement without necrosis or ductal dilation. These clues point to hypercalcemia from primary hyperparathyroidism as the etiology of pancreatitis, with stones as a classic manifestation. Main logical issue(s): None; the stem provides sufficient discriminating details to identify A as the unique best answer, with alternatives less fitting due to lack of supporting features (e.g., no IgG4 evidence for B, no family history or early onset for C, no triglyceride levels for D, no ulcer/diarrhea for E). Main medical accuracy issue(s): None; aligns with established knowledge that primary hyperparathyroidism causes hypercalcemia-induced pancreatitis (though uncommon) and nephrolithiasis, per guidelines like those from the American Association of Clinical Endocrinologists. The rationale correctly distinguishes from secondary causes. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-003", "question": "A 32-year-old woman presents with 3 weeks of progressive dyspnea and fatigue. Echocardiogram shows a large pericardial effusion with diastolic right atrial and right ventricular collapse. Right heart catheterization reveals equalization of diastolic pressures (RA 18, RV 18, PA 18/20, PCWP 18 mmHg). After pericardiocentesis of 800 mL of serosanguinous fluid, hemodynamics improve. Cytology is negative. Two days later, she develops recurrent dyspnea. Repeat echo shows reaccumulation of the effusion. The most appropriate definitive management is:", "options": ["Repeat pericardiocentesis and initiate colchicine", "Surgical creation of a pericardial window via subxiphoid approach", "Initiation of high-dose prednisone for suspected autoimmune pericarditis", "Pericardiectomy via left thoracotomy", "Intrapericardial instillation of bleomycin"], "answer": "B", "answer_index": 1, "explanation": "Recurrent symptomatic pericardial effusion with tamponade physiology, especially when cytology is negative (ruling out malignancy requiring specific therapy), is a clear indication for a definitive surgical procedure to prevent reaccumulation. A surgical pericardial window (subxiphoid or video-assisted) allows for drainage and biopsy. Pericardiectomy (D) is reserved for constrictive pericarditis. Steroids (C) are for inflammatory causes but are not definitive for recurrent effusion. Intrapericardial chemotherapy (E) is for malignant effusions.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent symptomatic pericardial effusion with tamponade physiology (diastolic collapse, equalized pressures), serosanguinous fluid, negative cytology, and rapid reaccumulation post-pericardiocentesis, implying need for definitive prevention of recurrence without evidence of malignancy or constriction. Main logical issue(s): none; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting B as uniquely best for drainage and biopsy. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., ESC/ACC) for managing recurrent idiopathic/non-malignant effusions via pericardial window to prevent reaccumulation, while alternatives are appropriately eliminated (A not definitive, C assumes unconfirmed autoimmune etiology, D for constriction, E for malignancy). Minimal fix: none needed, as the item is unambiguous and accurate. The clinical problem asks for definitive management of recurrent tamponading effusion. Discriminating findings: tamponade signs, negative cytology, serosanguinous nature, rapid recurrence. Implied: recurrent non-malignant effusion. Keyed B fits as it provides ongoing drainage. Alternatives: A temporary; C etiology unproven; D excessive; E irrelevant without malignancy.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent symptomatic pericardial effusion with tamponade physiology (diastolic collapse, equalized pressures), serosanguinous fluid, negative cytology, and rapid reaccumulation post-pericardiocentesis, implying need for definitive prevention of recurrence without evidence of malignancy or constriction. Main logical issue(s): none; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting B as uniquely best for drainage and biopsy. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., ESC/ACC) for managing recurrent idiopathic/non-malignant effusions via pericardial window to prevent reaccumulation, while alternatives are appropriately eliminated (A not definitive, C assumes unconfirmed autoimmune etiology, D for constriction, E for malignancy). Minimal fix: none needed, as the item is unambiguous and accurate. The clinical problem asks for definitive management of recurrent tamponading effusion. Discriminating findings: tamponade signs, negative cytology, serosanguinous nature, rapid recurrence. Implied: recurrent non-malignant effusion. Keyed B fits as it provides ongoing drainage. Alternatives: A temporary; C etiology unproven; D excessive; E irrelevant without malignancy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-004", "question": "A 70-year-old man with atrial fibrillation on apixaban (non-valvular) presents with acute onset of right-sided weakness and aphasia 4 hours after symptom onset. NIHSS is 15. CT head shows no hemorrhage. He is not a candidate for IV tPA due to anticoagulation. CT angiography shows a left M1 MCA occlusion. The most appropriate acute intervention is:", "options": ["Administer IV tPA after checking an INR and anti-Xa level", "Proceed directly to mechanical thrombectomy without thrombolysis", "Administer IV protamine to reverse apixaban, then give IV tPA", "Administer andexanet alfa, then give IV tPA", "Initiate IV heparin drip and observe for neurological improvement"], "answer": "B", "answer_index": 1, "explanation": "For patients with acute ischemic stroke and large vessel occlusion (LVO) who are not candidates for IV tPA, mechanical thrombectomy is the standard of care if performed within 24 hours of last known well and meeting other criteria (like NIHSS ≥6). Direct thrombectomy is non-inferior to bridging therapy (tPA + thrombectomy). Reversing anticoagulation to give tPA (C, D) delays definitive therapy and adds bleeding risk. Giving tPA on top of therapeutic anticoagulation (A) is contraindicated.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include 70-year-old with atrial fibrillation on apixaban, acute right-sided weakness and aphasia 4 hours post-onset, NIHSS 15, no hemorrhage on CT, left M1 MCA occlusion on CTA, and ineligibility for IV tPA due to anticoagulation. These point to acute ischemic stroke with large vessel occlusion (LVO), where mechanical thrombectomy is the standard intervention per AHA/ASA guidelines for tPA-ineligible patients within 24 hours if NIHSS ≥6. Main logical issue(s): None; the stem provides sufficient details to discriminate B as uniquely best without contradictions or underspecification. Alternatives are inferior: A risks bleeding from tPA on anticoagulation; C uses protamine (ineffective for apixaban); D delays therapy with andexanet reversal for non-standard bridging; E delays definitive treatment. Main medical accuracy issue(s): None; aligns with current evidence showing direct thrombectomy non-inferior to bridging in LVO, avoiding reversal risks. Minimal fix: None needed, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include 70-year-old with atrial fibrillation on apixaban, acute right-sided weakness and aphasia 4 hours post-onset, NIHSS 15, no hemorrhage on CT, left M1 MCA occlusion on CTA, and ineligibility for IV tPA due to anticoagulation. These point to acute ischemic stroke with large vessel occlusion (LVO), where mechanical thrombectomy is the standard intervention per AHA/ASA guidelines for tPA-ineligible patients within 24 hours if NIHSS ≥6. Main logical issue(s): None; the stem provides sufficient details to discriminate B as uniquely best without contradictions or underspecification. Alternatives are inferior: A risks bleeding from tPA on anticoagulation; C uses protamine (ineffective for apixaban); D delays therapy with andexanet reversal for non-standard bridging; E delays definitive treatment. Main medical accuracy issue(s): None; aligns with current evidence showing direct thrombectomy non-inferior to bridging in LVO, avoiding reversal risks. Minimal fix: None needed, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-005", "question": "A 55-year-old man with alcoholic cirrhosis (Child-Pugh B) is admitted with hepatic encephalopathy. He is started on lactulose. On day 3, he develops acute kidney injury. Serum sodium is 122 mEq/L (down from 128 on admission), creatinine 2.4 mg/dL (baseline 0.9), and he is clinically envolemic. Urine sodium is <10 mEq/L, urine osmolality 550 mOsm/kg. The most likely cause of his hyponatremia is:", "options": ["Syndrome of inappropriate antidiuretic hormone secretion (SIADH)", "Acute tubular necrosis from sepsis", "Hepatorenal syndrome type 1", "Pseudohyponatremia from hypertriglyceridemia", "Hyponatremia due to lactulose-induced diarrhea"], "answer": "E", "answer_index": 4, "explanation": "Lactulose causes an osmotic diarrhea, leading to loss of sodium and water, but relatively more water loss, resulting in hypertonic hyponatremia. The clinical picture (envolemic, high urine osmolality, low urine sodium) is consistent with volume depletion from GI losses, not SIADH (which has inappropriately high urine sodium). Hepatorenal syndrome (C) is characterized by low urine sodium but typically occurs in the setting of avid sodium retention and ascites, not acute diarrhea. ATN (B) would have high urine sodium.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (primary; secondary U leading to M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: Cirrhosis (Child-Pugh B), hepatic encephalopathy treated with lactulose, acute hyponatremia (128 to 122 mEq/L) with AKI (Cr 0.9 to 2.4 mg/dL), clinically euvolemic, urine Na <10 mEq/L, urine osm 550 mOsm/kg. These drive toward hypovolemic hyponatremia and prerenal AKI from diarrhea, but 'clinically euvolemic' contradicts hypovolemia. Main logical issue(s): Internal contradiction—euvolemic status conflicts with low urine Na and high urine osm typical of hypovolemia or hypervolemia, not euvolemic hyponatremia (which features high urine Na as in SIADH); underspecified details (e.g., ascites, volume challenge response) allow multiple defensible options (E vs. C). Main medical accuracy issue(s): Keyed E is plausible as lactulose can cause dehydration exacerbating hyponatremia in cirrhosis via non-osmotic ADH release, but provided rationale inaccurately describes 'hypertonic hyponatremia' and 'more water loss' (which would cause hypernatremia, not hypo); item implies unrealistic euvolemic hypovolemic state, contradicting standard classifications. Minimal fix: Change stem to 'clinically hypovolemic' to align with labs and support E uniquely as hypovolemic hyponatremia from diarrhea.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (primary; secondary U leading to M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: Cirrhosis (Child-Pugh B), hepatic encephalopathy treated with lactulose, acute hyponatremia (128 to 122 mEq/L) with AKI (Cr 0.9 to 2.4 mg/dL), clinically euvolemic, urine Na <10 mEq/L, urine osm 550 mOsm/kg. These drive toward hypovolemic hyponatremia and prerenal AKI from diarrhea, but 'clinically euvolemic' contradicts hypovolemia. Main logical issue(s): Internal contradiction—euvolemic status conflicts with low urine Na and high urine osm typical of hypovolemia or hypervolemia, not euvolemic hyponatremia (which features high urine Na as in SIADH); underspecified details (e.g., ascites, volume challenge response) allow multiple defensible options (E vs. C). Main medical accuracy issue(s): Keyed E is plausible as lactulose can cause dehydration exacerbating hyponatremia in cirrhosis via non-osmotic ADH release, but provided rationale inaccurately describes 'hypertonic hyponatremia' and 'more water loss' (which would cause hypernatremia, not hypo); item implies unrealistic euvolemic hypovolemic state, contradicting standard classifications. Minimal fix: Change stem to 'clinically hypovolemic' to align with labs and support E uniquely as hypovolemic hyponatremia from diarrhea.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-006", "question": "A 28-year-old pregnant woman at 32 weeks gestation is admitted for severe preeclampsia with BP 170/110 mmHg. She is started on IV magnesium sulfate for seizure prophylaxis and IV labetalol for blood pressure control. One hour after initiation of magnesium, she becomes somnolent, with loss of deep tendon reflexes. Respiratory rate is 8 breaths/min. Serum magnesium level is 9.2 mg/dL. After securing the airway, the most specific immediate treatment is:", "options": ["IV administration of 10% calcium gluconate 1 gram over 10 minutes", "IV administration of furosemide 40 mg to enhance renal excretion", "Immediate hemodialysis", "Discontinuation of magnesium sulfate and administration of IV levothyroxine", "IV administration of pyridostigmine 2 mg"], "answer": "A", "answer_index": 0, "explanation": "Calcium gluconate is the direct antagonist to the life-threatening cardiac and neuromuscular effects of hypermagnesemia. It stabilizes cardiac membranes and reverses respiratory depression caused by magnesium. Furosemide (B) promotes excretion but is not immediate. Dialysis (C) is for severe cases with renal failure but is not the first step after airway management. Pyridostigmine (E) is for myasthenia, not magnesium toxicity.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 28-year-old at 32 weeks gestation with severe preeclampsia (BP 170/110), on IV magnesium sulfate and labetalol; post-infusion somnolence, absent deep tendon reflexes, respiratory rate 8/min, serum magnesium 9.2 mg/dL (indicative of toxicity); airway secured. These drive diagnosis of hypermagnesemia causing neuromuscular and respiratory depression, requiring immediate antagonism. Main logical issues: None; stem provides sufficient details for unique best answer (A), with discriminable distractors. Main medical accuracy issues: None; aligns with ACOG guidelines for magnesium toxicity in preeclampsia—calcium gluconate as direct antagonist to reverse cardiac/neuromuscular effects after stopping infusion and supporting respiration. Item is clinically realistic and board-relevant.\\n\\nBest-answer defensibility:\\na) Question asks for most specific immediate treatment for magnesium toxicity post-airway management.\\nb) Discriminating findings: Elevated serum Mg (9.2 mg/dL), somnolence, absent DTRs, bradypnea; preeclampsia context justifies Mg use.\\nc) Implied: Hypermagnesemia toxicity; next step is pharmacologic antagonism.\\nd) Keyed A fits: Calcium gluconate directly counters Mg effects on membranes/neurons; assumes no contraindications (standard).\\ne) B worse: Diuresis aids excretion but not immediate reversal. C: Dialysis for refractory cases, not first-line. D: Levothyroxine irrelevant (thyroid-related). E: Pyridostigmine for cholinergic issues, not Mg toxicity.\\nMinimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 28-year-old at 32 weeks gestation with severe preeclampsia (BP 170/110), on IV magnesium sulfate and labetalol; post-infusion somnolence, absent deep tendon reflexes, respiratory rate 8/min, serum magnesium 9.2 mg/dL (indicative of toxicity); airway secured. These drive diagnosis of hypermagnesemia causing neuromuscular and respiratory depression, requiring immediate antagonism. Main logical issues: None; stem provides sufficient details for unique best answer (A), with discriminable distractors. Main medical accuracy issues: None; aligns with ACOG guidelines for magnesium toxicity in preeclampsia—calcium gluconate as direct antagonist to reverse cardiac/neuromuscular effects after stopping infusion and supporting respiration. Item is clinically realistic and board-relevant.\n\nBest-answer defensibility:\na) Question asks for most specific immediate treatment for magnesium toxicity post-airway management.\nb) Discriminating findings: Elevated serum Mg (9.2 mg/dL), somnolence, absent DTRs, bradypnea; preeclampsia context justifies Mg use.\nc) Implied: Hypermagnesemia toxicity; next step is pharmacologic antagonism.\nd) Keyed A fits: Calcium gluconate directly counters Mg effects on membranes/neurons; assumes no contraindications (standard).\ne) B worse: Diuresis aids excretion but not immediate reversal. C: Dialysis for refractory cases, not first-line. D: Levothyroxine irrelevant (thyroid-related). E: Pyridostigmine for cholinergic issues, not Mg toxicity.\nMinimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-007", "question": "A 62-year-old man with a history of asbestos exposure 30 years ago presents with unilateral right-sided pleural effusion. Thoracentesis reveals exudative fluid (by Light's criteria) with cytology positive for adenocarcinoma. PET-CT shows FDG-avid right pleural thickening and effusion, with no other distant metastases. The next best step in management is:", "options": ["Systemic chemotherapy with platinum-pemetrexed", "Pleurodesis followed by systemic chemotherapy", "Extrapleural pneumonectomy", "Pleurectomy/decortication followed by adjuvant chemoradiation", "Immunotherapy with pembrolizumab as first-line treatment"], "answer": "D", "answer_index": 3, "explanation": "This describes a likely diagnosis of malignant pleural mesothelioma (given asbestos exposure, unilateral effusion, pleural thickening). For resectable disease (stage I-III) in a fit patient, the standard of care is maximal cytoreductive surgery (pleurectomy/decortication) followed by adjuvant chemotherapy and possibly radiation. Extrapleural pneumonectomy (C) is a more radical, less commonly performed option. Systemic therapy alone (A) is for unresectable disease. Pleurodesis (B) is palliative.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (primary; secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: Asbestos exposure suggests mesothelioma, unilateral exudative effusion with FDG-avid pleural thickening and no distant metastases implies localized disease, but cytology positive for adenocarcinoma points to glandular malignancy (e.g., lung origin). Main logical issue(s): Contradiction between cytology (adenocarcinoma, inconsistent with mesothelioma) and other clues implying malignant pleural mesothelioma (MPM), rendering the item incoherent and unsolvable without assuming unstated diagnostic clarification (e.g., IHC to distinguish); this underspecification prevents identifying a unique best management step. Main medical accuracy issue(s): MPM is a mesothelial malignancy, not typically classified as adenocarcinoma; labeling cytology as adenocarcinoma misrepresents standard pathology, contradicts mainstream diagnostic criteria (e.g., NCCN guidelines for MPM requiring IHC for confirmation), and could mislead on differential diagnosis between MPM and metastatic adenocarcinoma. If intended as MPM, the keyed answer (D) aligns with resectable MPM management (pleurectomy/decortication + adjuvant therapy), but stem facts support alternatives like A for advanced adenocarcinoma. Minimal fix: Revise cytology to 'malignant cells consistent with epithelioid mesothelioma' to eliminate contradiction and align with accurate MPM diagnosis.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (primary; secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: Asbestos exposure suggests mesothelioma, unilateral exudative effusion with FDG-avid pleural thickening and no distant metastases implies localized disease, but cytology positive for adenocarcinoma points to glandular malignancy (e.g., lung origin). Main logical issue(s): Contradiction between cytology (adenocarcinoma, inconsistent with mesothelioma) and other clues implying malignant pleural mesothelioma (MPM), rendering the item incoherent and unsolvable without assuming unstated diagnostic clarification (e.g., IHC to distinguish); this underspecification prevents identifying a unique best management step. Main medical accuracy issue(s): MPM is a mesothelial malignancy, not typically classified as adenocarcinoma; labeling cytology as adenocarcinoma misrepresents standard pathology, contradicts mainstream diagnostic criteria (e.g., NCCN guidelines for MPM requiring IHC for confirmation), and could mislead on differential diagnosis between MPM and metastatic adenocarcinoma. If intended as MPM, the keyed answer (D) aligns with resectable MPM management (pleurectomy/decortication + adjuvant therapy), but stem facts support alternatives like A for advanced adenocarcinoma. Minimal fix: Revise cytology to 'malignant cells consistent with epithelioid mesothelioma' to eliminate contradiction and align with accurate MPM diagnosis.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-008", "question": "A 40-year-old woman presents with palpitations, heat intolerance, and weight loss. TSH is <0.01 mIU/L, free T4 is 3.2 ng/dL (high). Thyroid ultrasound shows a 2 cm hypoechoic nodule in the right lobe. Radioactive iodine uptake scan shows diffusely increased uptake (45% at 24 hours) with a photopenic area corresponding to the nodule. The most likely diagnosis is:", "options": ["Graves' disease with a coexisting cold nodule", "Toxic multinodular goiter", "Subacute thyroiditis", "Factitious thyrotoxicosis", "Marine-Lenhart syndrome (Graves' disease with a functioning nodule)"], "answer": "A", "answer_index": 0, "explanation": "The diffusely increased uptake is diagnostic of Graves' disease. The photopenic ('cold') nodule within an area of diffusely high uptake indicates a non-functioning nodule, which raises concern for malignancy and requires FNA biopsy. Marine-Lenhart syndrome (E) is Graves' with a *functioning* (hot) nodule. Toxic MNG (B) would show multiple areas of increased uptake. Subacute thyroiditis (C) shows very low uptake.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Symptoms of hyperthyroidism (palpitations, heat intolerance, weight loss), suppressed TSH with elevated free T4, ultrasound showing a 2 cm hypoechoic nodule, and RAIU with diffusely increased uptake (45% at 24 hours) but a photopenic (cold) area corresponding to the nodule. These point to Graves' disease as the underlying cause of thyrotoxicosis, with a coexisting non-functioning nodule.\\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification. A single best answer (A) is defensible, as diffuse high uptake rules out C (low uptake in subacute thyroiditis) and D (low/normal in factitious), while the cold nodule distinguishes from E (hot nodule in Marine-Lenhart) and B (multiple hot areas in toxic MNG).\\nMain medical accuracy issue(s), if any: None; aligns with standard endocrinology knowledge—Graves' features diffuse RAIU elevation, cold nodules warrant evaluation for malignancy, and distinctions from alternatives are precise per ATA guidelines.\\nMinimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Symptoms of hyperthyroidism (palpitations, heat intolerance, weight loss), suppressed TSH with elevated free T4, ultrasound showing a 2 cm hypoechoic nodule, and RAIU with diffusely increased uptake (45% at 24 hours) but a photopenic (cold) area corresponding to the nodule. These point to Graves' disease as the underlying cause of thyrotoxicosis, with a coexisting non-functioning nodule.\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification. A single best answer (A) is defensible, as diffuse high uptake rules out C (low uptake in subacute thyroiditis) and D (low/normal in factitious), while the cold nodule distinguishes from E (hot nodule in Marine-Lenhart) and B (multiple hot areas in toxic MNG).\nMain medical accuracy issue(s), if any: None; aligns with standard endocrinology knowledge—Graves' features diffuse RAIU elevation, cold nodules warrant evaluation for malignancy, and distinctions from alternatives are precise per ATA guidelines.\nMinimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-009", "question": "A 50-year-old man with diabetes mellitus and hypertension is found to have a serum potassium of 6.8 mEq/L on routine labs. He is asymptomatic. ECG shows peaked T waves. He is given IV calcium gluconate, insulin/dextrose, and albuterol. His potassium decreases to 6.0 mEq/L. Renal function is normal. Further workup reveals a low serum aldosterone and elevated plasma renin activity. The most likely cause of his hyperkalemia is:", "options": ["Type 4 renal tubular acidosis (hyporeninemic hypoaldosteronism)", "Addison's disease", "Gordon's syndrome (pseudohypoaldosteronism type II)", "Spironolactone use", "Rhabdomyolysis"], "answer": "C", "answer_index": 2, "explanation": "Gordon's syndrome (familial hyperkalemic hypertension) is characterized by hyperkalemia, hypertension, normal GFR, metabolic acidosis, and *suppressed* renin but *normal or high* aldosterone. The key here is the elevated renin, which rules out hyporeninemic hypoaldosteronism (A, which has low renin and low aldosterone) and points to a primary renal defect in potassium excretion. Addison's (B) has low aldosterone and high renin but also has hyponatremia and hypotension.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: N (secondary U). Verdict on keyed answer: No defensible answer. Key stem clues that drive (or fail to drive) a unique best answer: hyperkalemia (6.8 to 6.0 mEq/L post-treatment), history of hypertension and diabetes, normal renal function, low serum aldosterone, elevated plasma renin activity, asymptomatic with peaked T waves. These clues suggest hypoaldosteronism with compensatory high renin, but HTN and lack of other details (e.g., current BP, sodium, acid-base) prevent clear diagnosis. Main logical issue(s): No option is defensible— A requires low renin (contradicts elevated renin); B (Addison's) typically causes hypotension and hyponatremia (contradicts HTN history, underspecified Na/BP); C (Gordon's) typically has suppressed renin (contradicts elevated renin); D requires high aldosterone (contradicts low aldosterone); E (rhabdomyolysis) implies acute process with possible AKI (contradicts normal GFR and chronic presentation). Item is underspecified, leading to no defensible best answer. Main medical accuracy issue(s): Keyed C is inaccurate; Gordon's syndrome classically features low renin and normal/low aldosterone, not elevated renin/low aldosterone as in stem; rationale incorrectly claims elevated renin points to C while describing suppressed renin for Gordon's, misleading learners on pathophysiology. Minimal fix: Revise stem to 'suppressed plasma renin activity' and 'normal aldosterone' to align with Gordon's features and support key C unambiguously.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"N\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (secondary U). Verdict on keyed answer: No defensible answer. Key stem clues that drive (or fail to drive) a unique best answer: hyperkalemia (6.8 to 6.0 mEq/L post-treatment), history of hypertension and diabetes, normal renal function, low serum aldosterone, elevated plasma renin activity, asymptomatic with peaked T waves. These clues suggest hypoaldosteronism with compensatory high renin, but HTN and lack of other details (e.g., current BP, sodium, acid-base) prevent clear diagnosis. Main logical issue(s): No option is defensible— A requires low renin (contradicts elevated renin); B (Addison's) typically causes hypotension and hyponatremia (contradicts HTN history, underspecified Na/BP); C (Gordon's) typically has suppressed renin (contradicts elevated renin); D requires high aldosterone (contradicts low aldosterone); E (rhabdomyolysis) implies acute process with possible AKI (contradicts normal GFR and chronic presentation). Item is underspecified, leading to no defensible best answer. Main medical accuracy issue(s): Keyed C is inaccurate; Gordon's syndrome classically features low renin and normal/low aldosterone, not elevated renin/low aldosterone as in stem; rationale incorrectly claims elevated renin points to C while describing suppressed renin for Gordon's, misleading learners on pathophysiology. Minimal fix: Revise stem to 'suppressed plasma renin activity' and 'normal aldosterone' to align with Gordon's features and support key C unambiguously.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-010", "question": "A 65-year-old man with a mechanical aortic valve (On-X) on warfarin presents with a transient ischemic attack. INR on presentation is 1.8 (target 2.5-3.5). He has no bleeding history. The most appropriate adjustment to his antithrombotic regimen is:", "options": ["Increase warfarin dose to achieve INR 2.5-3.5; add aspirin 81 mg daily", "Increase warfarin dose to achieve INR 2.5-3.5; no aspirin needed", "Switch to apixaban 5 mg twice daily", "Add clopidogrel 75 mg daily to current warfarin therapy", "Discontinue warfarin and initiate dual antiplatelet therapy with aspirin and clopidogrel"], "answer": "A", "answer_index": 0, "explanation": "For a mechanical aortic valve, the standard of care is warfarin with a target INR of 2.5-3.5. In patients who have a thromboembolic event despite therapeutic INR, adding aspirin 75-100 mg is recommended. Since his INR was subtherapeutic at the time of the TIA, the first step is to optimize INR control. However, given the event, adding low-dose aspirin is now indicated based on PROACT and other trials. Direct oral anticoagulants (C) are contraindicated in mechanical valves. Dual antiplatelet therapy (E) is inferior to warfarin for valve protection.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 65-year-old man with On-X mechanical aortic valve on warfarin, INR 1.8 (stated target 2.5-3.5, subtherapeutic), presents with TIA, no bleeding history; question asks for most appropriate antithrombotic adjustment. Main logical issue(s): The stem is underspecified regarding whether the patient is already on aspirin, a critical detail, as guidelines recommend low-dose aspirin for all mechanical valves; this leads to multiple defensible answers (A if not on aspirin, B if already on it, since event occurred at subtherapeutic INR). Options C, D, and E are clearly inferior (DOACs contraindicated, clopidogrel not standard, DAPT inferior to VKA). Main medical accuracy issue(s): Stated INR target 2.5-3.5 is incorrect for On-X aortic valve (standard is 1.5-2.0 with aspirin per PROACT/FDA; general aortic target is 2-3); aspirin is Class I recommendation for all mechanical valves regardless of event, not specifically 'given the event' as rationale implies; INR 1.8 would be therapeutic under accurate On-X target, altering the clinical problem. Minimal fix: Add to stem: 'not currently on antiplatelet therapy' and revise target to '1.5-2.0'.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 65-year-old man with On-X mechanical aortic valve on warfarin, INR 1.8 (stated target 2.5-3.5, subtherapeutic), presents with TIA, no bleeding history; question asks for most appropriate antithrombotic adjustment. Main logical issue(s): The stem is underspecified regarding whether the patient is already on aspirin, a critical detail, as guidelines recommend low-dose aspirin for all mechanical valves; this leads to multiple defensible answers (A if not on aspirin, B if already on it, since event occurred at subtherapeutic INR). Options C, D, and E are clearly inferior (DOACs contraindicated, clopidogrel not standard, DAPT inferior to VKA). Main medical accuracy issue(s): Stated INR target 2.5-3.5 is incorrect for On-X aortic valve (standard is 1.5-2.0 with aspirin per PROACT/FDA; general aortic target is 2-3); aspirin is Class I recommendation for all mechanical valves regardless of event, not specifically 'given the event' as rationale implies; INR 1.8 would be therapeutic under accurate On-X target, altering the clinical problem. Minimal fix: Add to stem: 'not currently on antiplatelet therapy' and revise target to '1.5-2.0'.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}]